# **Whole genome analysis in** *APOE4* **homozygotes identifies the** *DAB1-RELN*

# **pathway in Alzheimer's disease pathogenesis**

- 
- 4 Matthew Bracher-Smith, PhD<sup>1</sup>, Ganna Leonenko, PhD<sup>2</sup>, Emily Baker, PhD<sup>2</sup>, Karen Crawford, MSc<sup>1</sup>,
- 5 Andrew C. Graham, MSc<sup>3</sup>, Dervis A. Salih, PhD<sup>3</sup>, Brian W. Howell, PhD<sup>4</sup>, John Hardy, PhD<sup>3\*</sup>, Valentina
- Escott-Price, PhD<sup>1,2\*</sup>
- 
- *Affiliations*
- 9 1 MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine &
- Clinical Neurosciences, Cardiff University, UK
- 2 Dementia Research Institute, Cardiff University, UK
- 3 Dementia Research Institute, University College London, UK
- 4 Neuroscience and Physiology, State University of New York, USA
- 
- *Corresponding Authors*
- Valentina Escott-Price
- Tel. +44 2920 688429
- Address: Hadyn Ellis Building, Cardiff University, Maindy Road, Cardiff, CF24 4HQ, UK
- e-mail: escottpricev@cardiff.ac.uk
- 
- John Hardy
- Tel. +44 2031 086802
- Address: UCL Cruciform Building, Gower Street, London, WC1E 6BT, UK
- e-mail: j.hardy@ucl.ac.uk
- 

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## **Abstract**



#### **Introduction**





*Genetic quality control*





It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.28.22274418;](https://doi.org/10.1101/2022.04.28.22274418) this version posted April 28, 2022. The copyright holder for this preprint

- *RELN, LRP8, VLDLR, DAB1, SRC, FYN, YES1, b) CRK, CRKL, RAPGEF1, RAP1A, CTNND, CDH2, c)*
- *PIK3CA, PDK1, PDK2, GSK3B, AKT1, STK25.*
- 
- 
- **Results**
- We present the results in the following order: (a) analysis of the *APOE* locus, (b) analysis of
- other previously reported GWAS in these cases, (c) identification of the *DAB1* locus as a
- genome wide for disease, (d) assessment of other loci in the same *DAB1-RELN* pathway.
- 
- *APOE* locus
- No suggestive variants were identified in the *APOE* gene or surrounding region
- (chromosome 19: 44.5-46.5 Mb, as defined previously [23]) with the lowest *p*-value at 0.003
- within 1Mb of the *APOE* gene (Supplementary Figure S1) in *APOE-*e4 homozygotes.
- 
- *Other GWAS Hits*
- Loci previously reported as GWAS for association with Alzheimer's disease status did not
- 146 show a strong replication in the current analysis of *APOE*- $\varepsilon$ 4 homozygotes only
- (Supplemental Table S1). Though the power to detect the GWAS-reported effect sizes in this
- sample is not sufficient (see last column of Supplemental Table S1), four loci in *CD33*

(*p*=0.004), *IQCK* (*p*=0.009), *LILRB2* (*p*=0.005) and *SORL1* (*p*=0.007, MAF=0.04) had the

- strongest evidence for association in the current analysis and a consistent direction of effect
- between the current and previous GWAS. Weaker but nominally significant associations
- with the consistent direction of the effect were also observed in the *APH1B* (*p* = 0.024), *BIN1*





 interaction with *APOE*-e4 in the whole UK Biobank sample. The interaction term was not 201 significant (p=0.24), however the pattern of AD risk based on the pair of these markers was similar to *DAB1* (Supplemental Figure S4).



220 Using the results of the gene-based analyses described above, we tested whether the 221 receptor complex and the two pathway branches contained significantly more AD 222 associated genes as compared with the rest of the genome. We found that they were



*Other established GWAS hits*

 This study does not have statistical power to reliably determine whether all the previously reported GWAS hits are associated with disease in *APOE-*e4 homozygotes or whether those which do show direct evidence for association (nominal significance) are grouped in any particular pathway.

*Association with DAB1*

 Putative novel risk SNPs with strong evidence for association were mapped to the *DAB1* gene on chromosome 1. Roles for *DAB1* and *RELN* have previously been suggested in AD primarily based on studies in mice [36, 45–48] and functional genomic analysis in humans [49], but genome-wide association in humans has been lacking. However, it has been shown that the expression of *DAB1* and *RELN* are altered in AD brains [50–52]. DAB1 interacts with Asp-Pro-any residue-Tyr (NPXY) motifs in the cytoplasmic domains of amyloid precursor 258 protein (APP) as it does with similar motifs in the cytoplasmic tails of the Reelin receptors through its N-terminal PTB domain [53, 54]. The NPXY motif is required for APP 260 internalization and its deletion reduces A $\beta$  production [55]. DAB1 association with APP has 261 been shown to reduce amyloidogenic processing [36], which suggests it is involved in the 262 intracellular trafficking of APP. Reelin also reduces A $\beta$  production in HEK293 cells that don't express DAB1 [47]. In a mouse model of AD, heterozygosity of *Reln* increases the accumulation of AB plaques [45], suggesting that the pathway physiologically alters APP cleavage in a manner that would protect against AD. In addition, homozygous loss-of- function in *Reln* and *Dab1* have been shown to augment tau-phosphorylation [21]. Reelin overexpression reduces abnormal somatodendritic localization of phosphor-Tau, A $\beta$  plaques and synaptic loss in AD model mice [46, 48]. Thus there are links between the Reelin-DAB1



 The dependence of the association between *DAB1*/*RELN* and AD on *APOE-*e4 homozygosity is intriguing since there are several links between the Reelin pathway and APOE. The Reelin 278 receptors are also APOE receptors and DAB1 binds the NPXY motifs in the cytoplasmic tails of other LDL-superfamily receptors [53, 54, 56], such as LDL-receptor related protein 1 that has roles in APOE/Ab internalization and clearance [57]. Recent studies show that *APOE-*e*4* 281 reduces recycling of ApoER2 back to the plasma membrane making the cells less responsive 282 to Reelin [58] and that Reelin protects against the toxic effects of A $\beta$  on synapses [59]. Thus in *APOE*-e4 homozygotes, one can imagine a threshold effect with high *APOE*-e4 driving a pathological cycle by reducing the effects of DAB1 and RELN signalling including its normal 285 function to reduce AB production/toxicity and/or MAPT-phosphorylation.

 While the effect the SNPs have on the function of *DAB1* or other pathway genes remain to be determined, based on previous studies it would seem likely that they cause a partial loss-289 of-function that is potentially age dependent or cell-type specific in nature and would result in altered expression (eQTL) or splicing (sQTL). More than partial disruption of activity would 291 likely lead to a developmental disorder in the homozygous individuals similar to loss-of-

 function alleles for *Dab1* in mice and *RELN* in humans and mice [60]. The significant SNPs identified here fall in intron 2 and are found in 4-7% of the population. Interestingly *DAB1* exomic variation is constrained and few variants are more prevalent than 1-2% (GnomAD) suggesting that the identified SNPs do not flag an alteration in the *DAB1* coding sequence. *DAB1* is alternatively spliced and differentially expressed most notably in a cell-type specific manner [26, 61–63]. Alternative splicing has been shown to regulate exons encoding a subset of the phosphorylation sites and a C-terminal exon altering *Dab1* functionality in mice. We note that humans have a read through variant of exon 3 that would lead to transcriptional termination 14 residues later (variant 9) that has not been identified in mice. It encodes the first part of the phosphotyrosine binding (PTB) domain residues 37-69, but it is likely to be functionally inert since the PTB domain extends to residue 171 [64]. With this complexity and the size of the *DAB1* gene, over 1 Mb, it could take significant effort to dissect the consequence of the SNPs identified here on gene function and AD. In conclusion, we find a novel genome-wide significant hit in *DAB1* in an *APOE-*e4 homozygote AD GWAS. This seems to be a hit only in *APOE-*e4 homozygotes. Furthermore, it seems that this association marks a more general importance of the *DAB1-RELN* pathway in disease pathogenesis. It is not clear why this pathway should be of such importance in *APOE-*e4 homozygotes only, but a clue may be that such individuals have particularly dense AB pathology and one can imagine that this pathway either has a role in modulating APP processing or in driving tau-phosphorylation in a manner that is dependent on high Aβ levels. This work suggests that *DAB1* has a protective role in late onset AD and highlights the importance of resolving the mechanism that likely involves the REELIN-DAB1 pathway for

therapeutic development.

## **Funding**

- This work was largely funded by the UK DRI, which receives its funding from the DRI Ltd,
- funded by the UK Medical Research Council (UKDRI-3003), Alzheimer's Society and ARUK. JH
- 320 is supported by the Dolby Foundation, and by the National Institute for Health Research
- University College London Hospitals Biomedical Research Centre. D.A.S. also received
- funding from the Alzheimer's Research UK (ARUK) pump priming scheme via the UCL
- network. VEP is supported by Joint Programming for Neurodegeneration (JPND) (MRC:
- MR/T04604X/1).

#### **Competing interests**

The authors report no competing interests.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.28.22274418;](https://doi.org/10.1101/2022.04.28.22274418) this version posted April 28, 2022. The copyright holder for this preprint

#### **References**

- 1. Hardy J, Escott-Price V. Genes, pathways and risk prediction in Alzheimer's disease.
- Hum Mol Genet 2019; 28: R235–R240.
- 2. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson J V., Lince DH, et al. A High-
- Density Whole-Genome Association Study Reveals That *APOE* Is the Major
- Susceptibility Gene for Sporadic Late-Onset Alzheimer's Disease. J Clin Psychiatry
- 2007; 68: 0–0.
- 3. Leonenko G, Shoai M, Bellou E, Sims R, Williams J, Hardy J, et al. Genetic risk for
- alzheimer disease is distinct from genetic risk for amyloid deposition. Ann Neurol
- 2019; 86: 427–435.
- 4. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A
- genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 2021 539 2021; 53: 1276–1282.
- 5. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open
- Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of
- Middle and Old Age. PLOS Med 2015; 12: e1001779.
- 6. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
- resource with deep phenotyping and genomic data. Nature 2018; 562: 203–209.
- 7. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
- PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015; 4: 7.
- 8. Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, et al.
- LocusZoom.js: interactive and embeddable visualization of genetic association study

results. Bioinformatics 2021; 37: 3017–3018.

9. Hunter JD. Matplotlib. Comput Sci Eng 2007; 9: 90–95.

- 10. Leeuw CA de, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set
- Analysis of GWAS Data. PLoS Comput Biol 2015; 11.
- 11. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and
- annotation of genetic associations with FUMA. Nat Commun 2017 81 2017; 8: 1–11.
- 12. Lee GH, D'Arcangelo G. New insights into reelin-mediated signaling pathways. Front
- Cell Neurosci 2016; 10: 122.
- 13. Arnaud L, Ballif BA, Förster E, Cooper JA. Fyn Tyrosine Kinase Is a Critical Regulator of
- Disabled-1 during Brain Development. Curr Biol 2003; 13: 9–17.
- 14. Bock HH, Herz J. Reelin Activates Src Family Tyrosine Kinases in Neurons. Curr Biol 2003; 13: 18–26.
- 15. D'Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T. Reelin Is a Ligand for Lipoprotein Receptors. Neuron 1999; 24: 471–479.
- 16. Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, et al.
- Direct Binding of Reelin to VLDL Receptor and ApoE Receptor 2 Induces Tyrosine
- Phosphorylation of Disabled-1 and Modulates Tau Phosphorylation. Neuron 1999; 24: 481–489.
- 17. Ballif BA, Arnaud L, Arthur WT, Guris D, Imamoto A, Cooper JA. Activation of a
- Dab1/CrkL/C3G/Rap1 Pathway in Reelin-Stimulated Neurons. Curr Biol 2004; 14: 606– 610.
- 18. Franco SJ, Martinez-Garay I, Gil-Sanz C, Harkins-Perry SR, Müller U. Reelin Regulates
- Cadherin Function via Dab1/Rap1 to Control Neuronal Migration and Lamination in the Neocortex. Neuron 2011; 69: 482–497.
- 19. Jossin Y, Cooper JA. Reelin, Rap1 and N-cadherin orient the migration of multipolar neurons in the developing neocortex. Nat Neurosci 2011 146 2011; 14: 697–703.



- Kinase Interacts with the Adaptor Protein Dab1 in Response to Reelin Signaling and Is
- Required for Normal Cortical Lamination \*. J Biol Chem 2003; 278: 38772–38779.
- 21. Brich J, Shie FS, Howell BW, Li R, Tus K, Wakeland EK, et al. Genetic Modulation of Tau
- Phosphorylation in the Mouse. J Neurosci 2003; 23: 187–192.
- 22. Matsuki T, Zaka M, Guerreiro R, van der Brug MP, Cooper JA, Cookson MR, et al.
- Identification of Stk25 as a Genetic Modifier of Tau Phosphorylation in Dab1-Mutant
- Mice. PLoS One 2012; 7: e31152.
- 23. Escott-Price V, Shoai M, Pither R, Williams J, Hardy J. Polygenic score prediction
- captures nearly all common genetic risk for Alzheimer's disease. Neurobiol Aging
- 2017; 49: 214.e7-214.e11.
- 24. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-
- analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ,
- tau, immunity and lipid processing. Nat Genet 2019 513 2019; 51: 414–430.
- 25. Frieden C, Garai K. Structural differences between apoE3 and apoE4 may be useful in
- developing therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci U S A 2012;
- 109: 8913–8918.
- 26. Abadesco AD, Cilluffo M, Yvone GM, Carpenter EM, Howell BW, Phelps PE. Novel
- Disabled-1-expressing neurons identified in adult brain and spinal cord. Eur J Neurosci
- 2014; 39: 579–592.
- 27. Howell BW, Herrick TM, Cooper JA. Reelin-induced tryosine phosphorylation of
- Disabled 1 during neuronal positioning. Genes Dev 1999; 13: 643.
- 28. Howell BW, Herrick TM, Hildebrand JD, Zhang Y, Cooper JA. Dab1 tyrosine
- phosphorylation sites relay positional signals during mouse brain development. Curr

- Biol 2000; 10: 877–885.
- 29. Rice DS, Sheldon M, D'Arcangelo G, Nakajima K, Goldowitz D, Curran T. Disabled-1
- acts downstream of Reelin in a signaling pathway that controls laminar organization
- in the mammalian brain. Development 1998; 125: 3719–3729.
- 30. Qiu S, Weeber EJ. Reelin signaling facilitates maturation of CA1 glutamatergic
- synapses. J Neurophysiol 2007; 97: 2312–2321.
- 31. Ventruti A, Kazdoba TM, Niu S, D'Arcangelo G. Reelin deficiency causes specific
- defects in the molecular composition of the synapses in the adult brain. Neuroscience
- 2011; 189: 32–42.
- 32. Pujadas L, Gruart A, Bosch C, Delgado L, Teixeira CM, Rossi D, et al. Reelin Regulates
- Postnatal Neurogenesis and Enhances Spine Hypertrophy and Long-Term
- Potentiation. J Neurosci 2010; 30: 4636–4649.
- 33. Rogers JT, Rusiana I, Trotter J, Zhao L, Donaldson E, Pak DTS, et al. Reelin
- supplementation enhances cognitive ability, synaptic plasticity, and dendritic spine
- density. Learn Mem 2011; 18: 558–564.
- 34. Trotter J, Lee GH, Kazdoba TM, Crowell B, Domogauer J, Mahoney HM, et al. Dab1 Is
- Required for Synaptic Plasticity and Associative Learning. J Neurosci 2013; 33: 15652–
- 15668.
- 35. Weeber EJ, Beffert U, Jones C, Christian JM, Förster E, David Sweatt J, et al. Reelin and
- ApoE Receptors Cooperate to Enhance Hippocampal Synaptic Plasticity and Learning
- \*. J Biol Chem 2002; 277: 39944–39952.
- 36. Hoe H-S, Tran TS, Matsuoka Y, Howell BW, Rebeck GW. DAB1 and Reelin Effects on
- Amyloid Precursor Protein and ApoE Receptor 2 Trafficking and Processing \*. J Biol
- Chem 2006; 281: 35176–35185.



- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in
- Late Onset Families. Science (80- ) 1993; 261: 921–923.
- 38. Freudenberg-Hua Y, Li W, Davies P. Effects of Age, Sex, and Ethnicity on the
- Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-
- analysis. Front Med 2018; 0: 108.
- 39. Andrews SJ, Fulton-Howard B, Goate A. Interpretation of risk loci from genome-wide
- association studies of Alzheimer's disease. Lancet Neurol 2020; 19: 326–335.
- 40. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New
- insights into the genetic etiology of Alzheimer's disease and related dementias. Nat
- Genet 2022 544 2022; 54: 412–436.
- 41. Jun G, Vardarajan BN, Buros J, Yu C-E, Hawk M V., Dombroski BA, et al.
- Comprehensive Search for Alzheimer Disease Susceptibility Loci in the APOE Region.
- Arch Neurol 2012; 69: 1270–1279.
- 42. Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, et al. Common
- variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset
- Alzheimer's disease. Nat Genet 2011 435 2011; 43: 436–441.
- 43. Zhou X, Chen Y, Mok KY, Kwok TCY, Mok VCT, Guo Q, et al. Non-coding variability at
- the APOE locus contributes to the Alzheimer's risk. Nat Commun 2019 101 2019; 10:
- 1–16.
- 44. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, et
- al. A TOMM40 variable-length polymorphism predicts the age of late-onset
- Alzheimer's disease. Pharmacogenomics J 2010 105 2009; 10: 375–384.
- 45. Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, et al.





- Disabled-1 (DAB1), the Intracellular Adaptor of the Reelin Pathway, Reveals Unusual
- Complexity in Human and Mouse \*. J Biol Chem 2003; 278: 5802–5812.
- 61. D D, Hung K-Y, Tarn W-Y. RBM4 Modulates Radial Migration via Alternative Splicing of
- Dab1 during Cortex Development. Mol Cell Biol 2018; 38.
- 62. Gao Z, Godbout R. Reelin-Disabled-1 signaling in neuronal migration: splicing takes
- the stage. Cell Mol Life Sci 2012 7013 2012; 70: 2319–2329.
- 63. Yano M, Hayakawa-Yano Y, Mele A, Darnell RB. Nova2 Regulates Neuronal Migration
- through an RNA Switch in Disabled-1 Signaling. Neuron 2010; 66: 848–858.
- 64. Howell BW, Gertler FB, Cooper JA. Mouse disabled (mDab1): a Src binding protein
- implicated in neuronal development. EMBO J 1997; 16: 121–132.
- 65. Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, et al. GWAS on
- family history of Alzheimer's disease. Transl Psychiatry 2018 81 2018; 8: 1–7.
- 

## **Figure legends**

- **Figure 1:** Manhattan plot for the genome-wide association study in *APOE*-e4 homozygotes
- 513 with SNP MAF  $>$  5%.



- **Figure 2:** The cumulative risk of AD among *APOE*-e4 homozygous of the UK Biobank
- participants, who carry 0, 1 or 2 risk alleles T the lead SNP (rs112437613) in *DAB1.*



- **Figure 3.** Epistatic effect between *APOE*-e4 and rs112437613 (*DAB1*) in the whole sample of
- the UK Biobank aged 65+ (N=229,748). All log(odds ratio) values are with respect to the
- baseline homozygote with no counted alleles at both loc. Orange/red bars have negative
- values. All odds ratios are adjusted for age, sex and principal components.



- **Figure 4.** REELIN-DAB1 signalling pathway based on studies in mouse neurons and brain
- (human protein names are shown, created with BioRender.com, see BioRender's Academic
- License publication licence in the Supplemental material). The pathway branches
- downstream of the signalling complex. Branch 1 regulates the cell surface expression of
- CDH2 (N-cadherin) and branch 2 regulates MAPT phosphorylation.



#### **Table 1:** Novel genome-wide significant SNPs in *DAB1*.



CHR –chromosome; BP –base-pair position in build37; SNP –single nucleotide polymorphism, closest gene –genes were annotated with

assembly hg19; effect/non-effect –effect and non-effect alleles; freq- frequency of reference allele in the UK Biobank *APOE*-e4 homozygotes

individuals; OR, SE, p-value –odds ratio, standard error and p-value of the current and previous reported AD GWAS association studies; GWAS

538 – reference of the corresponding GWAS study

**Table 2.** Results of the gene-based analyses for the genes in the *DAB1-RELN* pathway

accounting for the number of SNPs and the LD structure for each gene using MAGMA

software.



GENE –gene annotation with assembly hg19; CHR- chromosome; START, STOP – start and stop base-pair positions for genes; N SNPs- the number of SNPs in the analysis, p-value for the gene-based association test.